基于SWOT分析模型评价我院抗肿瘤药物临床应用监管效果  

Effect evaluation of supervision on anti-tumor drugs clinical application in our hospital based on SWOT analysis model

作　　者：蒋婷[1] 袁明勇[1] 郑玲利[1] 刘朝敏[2] JIANG Ting;YUAN Mingyong;ZHENG Lingi;LIU Chaomin(Department of Pharmacy,the First Affiliated Hospital of Chengdu Medical College,Chengdu,610500,Sichuan,China;Department of Oncology,the First Affiliated Hospital of Chengdu Medical College,Chengdu,610500,Sichuan,China)

机构地区：[1]成都医学院第一附属医院药学部,四川成都610500 [2]成都医学院第一附属医院肿瘤科,四川成都610500

出　　处：《肿瘤药学》2023年第5期631-636,共6页Anti-Tumor Pharmacy

基　　金：四川省卫健委普及应用科研项目(20PJ155)。

摘　　要：目的以SWOT分析结果为切入点,分类构建及实施抗肿瘤药物临床应用监管策略,并对其应用效果进行评价,为抗肿瘤药物的临床应用管理提供参考和依据。方法分别于监管策略实施前和监管策略实施后随机抽取600例出院且医嘱涉及抗肿瘤药物使用的患者资料,分析比较策略实施前后抗肿瘤药物临床应用合理性变化情况。结果策略实施后,我院抗肿瘤药物临床应用不合理现象得到显著改善,尤其是在既往不合理用药较严重的非肿瘤科室及既往不合理用药较常见的类型,如给药剂量不合理、溶媒用量不合理、给药顺序不合理等,用药不合理率由干预前的19.5%下降到干预后的10.2%,差异具有统计学意义(P<0.05)。结论抗肿瘤药物临床应用监管策略的构建及实施有利于抗肿瘤药物合理规范使用。Objective To construct and implement the clinical application regulatory strategy of anti-tumor drugs ac-cording to SWOT analysis results,and evaluate its application effect,so as to provide reference and basis for the manage-ment of clinical application of anti-tumor drugs.Methods The data of 600 discharged patients whose medical orders in-volved the use of anti-tumor drugs were randomly selected before and after the implementation of the regulatory strategy.The changes in the rationality of clinical application of anti-tumor drugs before and after the implementation of the regulato-ry strategy were analyzed and compared.Results After the implementation of the strategy,the irrational clinical application of anti-tumor drugs in our hospital was significantly improved,especially in the non-tumor departments with serious irratio-nal drug use in the past and in the common types of irrational drug use in the past,such as unreasonable drug dosage,un-reasonable solvent dosage,unreasonable order of drug administration,etc.The irrational rate of medication decreased from 19.5%before intervention to 10.2%after intervention,and the difference was statistically significant(P<0.05).Conclusion The construction and implementation of the regulatory strategy for clinical application of anti-tumor drug is conducive to its rational and standardized use.

关 键 词：抗肿瘤药物 临床应用 监管策略 构建实施 效果评价 

分 类 号：R979.1[医药卫生—药品] R969.3[医药卫生—药学]